[Skip to Content]
[Skip to Content Landing]
Medical News & Perspectives
May 22/29, 2018

Taking a Closer Look at the Biomarker Test for Mild Traumatic Brain Injury

JAMA. 2018;319(20):2066-2067. doi:10.1001/jama.2018.4644

Not long after a first-of-its-kind blood test received approval to evaluate patients with mild traumatic brain injury, headlines dubbed it a “concussion test.” But experts in biomarkers are clarifying certain misconceptions about what the test can and can’t reveal.

“It’s used to rule out the need for a [computed tomography] scan within 12 hours” after a suspected mild traumatic brain injury (TBI), said Steven Richieri, MBA, president and chief operating officer of San Diego-based Banyan Biomarkers Inc, which developed the test.